Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates - A randomised double blind placebo controlled trial

Sanjay Patole, A.D. Keil, A. Chang, E.A. Nathan, Dorota Doherty, Karen Simmer, M. Esvaran, P.L. Conway

    Research output: Contribution to journalArticle

    59 Citations (Scopus)

    Abstract

    Background: Probiotic supplementation significantly reduces the risk of necrotising enterocolitis (NEC) and all cause mortality in preterm neonates. Independent quality assessment is important before introducing routine probiotic supplementation in this cohort. Aim: To assess product quality, and confirm that Bifidobacterium breve (B. breve) M-16V supplementation will increase fecal B. breve counts without adverse effects. Methods and Participants: Strain identity (16S rRNA gene sequencing), viability over 2 year shelf-life were confirmed, and microbial contamination of the product was ruled out. In a controlled trial preterm neonates (Gestation
    Original languageEnglish
    Pages (from-to)1-8
    JournalPLoS One
    Volume9
    Issue number3
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates - A randomised double blind placebo controlled trial'. Together they form a unique fingerprint.

  • Cite this